



BRIAN SANDOVAL  
Governor

STATE OF NEVADA  
DEPARTMENT OF HUMAN RESOURCES  
**DIVISION OF HEALTH CARE FINANCING AND POLICY**  
NEVADA MEDICAID  
**NOTICE OF OPEN PUBLIC MEETING**

MICHAEL J. WILLDEN  
Director

CHARLES DUARTE  
Administrator

The Division of Health Care Financing and Policy (DHCFP) Pharmacy and Therapeutics Committee will conduct a public meeting on **September 22, 2011**, beginning at **1:00 p.m.** at the following location:

**Las Vegas Chamber of Commerce  
6671 Las Vegas Blvd. S., Suite 300  
Las Vegas, NV 89119**

Some members will be attending the meeting via video conference at Nevada State Health Division, 4150 Technology Way, Suite 300, Carson City, Nevada 89506 (public seating is limited).

Reasonable efforts will be made to assist and accommodate physically challenged persons desiring to attend the meeting. Please call Rita Mackie at: 775-684-3681 or email [rmackie@dhcfp.nv.gov](mailto:rmackie@dhcfp.nv.gov) in advance, but no later than two working days prior to the meeting, so that arrangements may be conveniently made.

**Below is an agenda of all items scheduled to be considered. Unless otherwise noted, items may be taken out of order at the discretion of the Chairperson.**

**Public comment is limited to 5 minutes per individual, organization, or agency, but may be extended at the discretion of the Chairperson.**

**AGENDA**

- I. Call to Order and Roll Call
- II. For Possible Action: Review and Approval of the June 23, 2011 Meeting Minutes
- III. Proposed New Drug Classes
  - A. Anticoagulants
    - 1. Public Comment
    - 2. Drug Class Review Presentation – Magellan Medicaid Administration
    - 3. For Possible Action: Committee Discussion and Action
      - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
      - b. Identify Exclusions/Exceptions for Certain Patient Groups
    - 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Magellan Medicaid Administration and the Division of Health Care Financing and Policy
    - 5. For Possible Action: Committee Discussion and Approval of Drugs for Inclusion on the PDL
  - B. Bronchodilators for COPD
    - 1. Public Comment
    - 2. Drug Class Review Presentation – Magellan Medicaid Administration
    - 3. For Possible Action: Committee Discussion and Action
      - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
      - b. Identify Exclusions/Exceptions for Certain Patient Groups
    - 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Magellan Medicaid Administration and the Division of Health Care Financing and Policy

1100 E. William Street, Suite 102, Carson City, Nevada 89701  
(775) 684-3600

5. For Possible Action: Committee Discussion and Approval of Drugs for Inclusion on the PDL

#### IV. Established Drug Classes

##### C. Hepatitis C Agents

1. Public Comment
2. Drug Class Review Presentation – Magellan Medicaid Administration
3. For Possible Action: Committee Discussion and Action
  - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
  - b. Identify Exclusions/Exceptions for Certain Patient Groups
4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Magellan Medicaid Administration and the Division of Health Care Financing and Policy
5. For Possible Action: Committee Discussion and Approval of Drugs for Inclusion on the PDL

##### D. Cardiovascular: Angiotensin II Receptor Blockers and Diuretic Combinations

1. Public Comment
2. Drug Class Review Presentation – Magellan Medicaid Administration
3. For Possible Action: Committee Discussion and Action
  - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
  - b. Identify Exclusions/Exceptions for Certain Patient Groups
4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Magellan Medicaid Administration and the Division of Health Care Financing and Policy
5. For Possible Action: Committee Discussion and Approval of Drugs for Inclusion on the PDL

##### E. Cardiovascular: Direct Renin Inhibitors and Combinations

1. Public Comment
2. Drug Class Review Presentation – Magellan Medicaid Administration
3. For Possible Action: Committee Discussion and Action
  - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
  - b. Identify Exclusions/Exceptions for Certain Patient Groups
4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Magellan Medicaid Administration and the Division of Health Care Financing and Policy
5. For Possible Action: Committee Discussion and Approval of Drugs for Inclusion on the PDL

##### F. Diabetic Agents: Other Agents

1. Public Comment
2. Drug Class Review Presentation – Magellan Medicaid Administration
3. For Possible Action: Committee Discussion and Action
  - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
  - b. Identify Exclusions/Exceptions for Certain Patient Groups
4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Magellan Medicaid Administration and the Division of Health Care Financing and Policy
5. For Possible Action: Committee Discussion and Approval of Drugs for Inclusion on the PDL

##### G. Ophthalmic Antihistamines

1. Public Comment
2. Drug Class Review Presentation – Magellan Medicaid Administration
3. For Possible Action: Committee Discussion and Action
  - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
  - b. Identify Exclusions/Exceptions for Certain Patient Groups

4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Magellan Medicaid Administration and the Division of Health Care Financing and Policy
  5. For Possible Action: Committee Discussion and Approval of Drugs for Inclusion on the PDL
- H. Ophthalmic Non-Steroidal Anti-Inflammatory Agents
1. Public Comment
  2. Drug Class Review Presentation – Magellan Medicaid Administration
  3. For Possible Action: Committee Discussion and Action
    - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
    - b. Identify Exclusions/Exceptions for Certain Patient Groups
  4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Magellan Medicaid Administration and the Division of Health Care Financing and Policy
  5. For Possible Action: Committee Discussion and Approval of Drugs for Inclusion on the PDL
- I. Ophthalmic Quinolones
1. Public Comment
  2. Drug Class Review Presentation – Magellan Medicaid Administration
  3. For Possible Action: Committee Discussion and Action
    - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
    - b. Identify Exclusions/Exceptions for Certain Patient Groups
  4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Magellan Medicaid Administration and the Division of Health Care Financing and Policy
  5. For Possible Action: Committee Discussion and Approval of Drugs for Inclusion on the PDL
- J. Respiratory: Inhaled Corticosteroid/Beta-Adrenergic Combinations
1. Public Comment
  2. Drug Class Review Presentation – Magellan Medicaid Administration
  3. For Possible Action: Committee Discussion and Action
    - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
    - b. Identify Exclusions/Exceptions for Certain Patient Groups
  4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Magellan Medicaid Administration and the Division of Health Care Financing and Policy
  5. For Possible Action: Committee Discussion and Approval of Drugs for Inclusion on the PDL
- V. Report by Magellan on New Drugs to Market, New Generic Drugs to Market, and New Line Extensions
- VI. Review of Next Meeting Location, Date, and Time
- VII. Public Comment
- VIII. For Possible Action: Adjournment

This notice and agenda has been posted on or before 9:00 a.m. on the third working day before the meeting at the following locations:

**Notice of this meeting will be available on or after the posting date of this Agenda at the DHCFP Web site ([dhcfp.state.nv.us](http://dhcfp.state.nv.us)).**

**Posting of the Agenda will be at the Nevada Medicaid Central offices in Carson City and Las Vegas; Nevada State Library; Carson City Library; Churchill County Library; Las Vegas Library; Douglas County Library; Elko County Library; Lincoln County Library; Lyon County Library; Mineral County Library; Tonopah Public Library; Pershing County Library; Goldfield Public Library; Eureka Branch Library; Humboldt County Library; Lander County Library; Storey County Library; Washoe County Library; and White Pine County Library and may be reviewed during normal business hours.**

**If requested in writing, a copy of the action items will be mailed to you or they may be reviewed Monday through Friday from 9:00 a.m. until 5:00 p.m., or at the meeting. Please call at least one day ahead for an appointment for document review. Written comments on the proposed changes may be sent to the DHCFP, 1100 E. William Street, Suite 102, Carson City, NV 89701.**

**All persons that have requested in writing to receive the Open Meeting Agenda have been duly notified by mail or e-mail.**

**Anyone presenting documents for consideration during the public comment portion of the meeting must provide sufficient copies for each member of the committee and the official record. Copies are to be distributed at the time of the meeting and should be provided at both meeting locations; DHCFP or its contractor will not distribute public comment information or materials prior to the public meeting.**